{"id":1264,"date":"2026-08-26T09:27:25","date_gmt":"2026-08-26T12:27:25","guid":{"rendered":"https:\/\/tirzeclub.com.br\/?p=1264"},"modified":"2026-08-26T15:53:23","modified_gmt":"2026-08-26T18:53:23","slug":"tirzepatida-gordura-no-figado","status":"publish","type":"post","link":"https:\/\/tirzeclub.com.br\/en\/tirzepatida-gordura-no-figado\/","title":{"rendered":"Tirzepatida, and the fat of the liver: what the studies show"},"content":{"rendered":"

To fat in the liver<\/strong> this is a change in metabolism is very common in persons with overweight, obesity, insulin resistance, and type 2 diabetes. For a very long time, it was primarily known as steatosis of the liver, non-alcoholic. Now, with the naming the current use of the term disease of the liver, esteat\u00f3tica associated with metabolic dysfunction, or MASLD.<\/p>\n\n\n\n

The relationship between the Tirzepatida and fat in the liver<\/strong> went on to call the attention because of the medicine, it produces a loss of a significant, improvement in parameters of glucose and works on mechanisms related to insulin sensitivity. In addition, clinical studies have already evaluated directly on the amount of fat, the liver, and in patients with more advanced disease, and have also examined the inflammation, and fibrosis.<\/p>\n\n\n\n

The results are promising, but need to be interpreted correctly. The Tirzepatida should not be presented as a medicine specifically approved to treat steatosis, or MASH only on the basis of these studies.<\/p>\n\n\n\n

In this article, you are going to understand that it is the steatosis of the liver, because it is related to the body's metabolism, which in the study with the Tirzepatida they met, and what care is still important, even during the treatment.<\/p>\n\n\n\n

\n

- Important:<\/strong> this content is purely informative and does not replace evaluation by a doctor. The changes in the liver, which may be due to several causes, and it needs to be investigated properly.<\/p>\n<\/blockquote>\n\n\n\n

That means you have to have fat in the liver?<\/h2>\n\n\n\n

Have fat in the liver<\/strong> this means that there is excessive accumulation of fat in the cells of the liver.<\/p>\n\n\n\n

On the way to a metabolic disease that is now called the MASLD, also known as English language metabolic dysfunction-associated steatotic liver disease<\/em>.<\/p>\n\n\n\n

According to the NIDDK, the MASLD is associated with the accumulation of fat in liver and is known to appear, along with the factors that cardiometab\u00f3licos, such as obesity, type 2 diabetes, insulin resistance, alterations in cholesterol and high blood pressure.<\/p>\n\n\n\n

Not every person with steatosis has an inflammation or scarring of the organ.<\/p>\n\n\n\n

For this reason, there is a big difference between a book store fat and developing the most advanced forms of the disease.<\/p>\n\n\n\n

MASLD and MASH are one and the same thing.<\/h2>\n\n\n\n

No.<\/p>\n\n\n\n

The MASLD it encompasses a spectrum of changes.<\/p>\n\n\n\n

In some patients, there is mainly the accumulation of fat, with little or no inflammation or liver damage is important.<\/p>\n\n\n\n

On the other, the fat in the liver<\/strong> is accompanied by inflammation of and damage to the cells of the body.<\/p>\n\n\n\n

When this happens, the framework can also be called the MASH, also known as metabolic dysfunction-associated steatohepatitis<\/em>.<\/p>\n\n\n\n

The MASH that deserves more attention because it can be traced back to the formation of fibrosis, which is a kind of healing for the liver.<\/p>\n\n\n\n

Over time, fibrosis can progress on to a couple of people and get to cirrhosis.<\/p>\n\n\n\n

By which steatosis is so linked to insulin resistance?<\/h2>\n\n\n\n

The resistance to the insulin that changes the way the different fabrics they use and store energy.<\/p>\n\n\n\n

When the adipose tissue is less sensitive to the insulin that is, there may be a greater release of fatty acids into the circulation. These fatty acids can come from the liver, and contribute to the accumulation of fat.<\/p>\n\n\n\n

In addition, changes in the production in the liver, fat, and glucose metabolism are also involved in this process.<\/p>\n\n\n\n

For this reason, fat in the liver<\/strong>, abdominal obesity, triglyceride levels, insulin resistance, and type 2 diabetes often appear together.<\/p>\n\n\n\n

In this connection, it helps to understand the treatment, which produces a loss of weight and improvement in metabolism, may also have an impact on the health of the liver.<\/p>\n\n\n\n

The fat is in the liver, usually the symptoms?<\/h2>\n\n\n\n

Often, they don't.<\/p>\n\n\n\n

The NIDDK describes the disease is often silent, with few or no symptoms at all.<\/p>\n\n\n\n

When there are no symptoms, some people may experience:<\/p>\n\n\n\n

    \n
  • unusual tiredness;<\/li>\n\n\n\n
  • discomfort in the upper right part of the abdomen;<\/li>\n\n\n\n
  • the feeling is argued from a land-line.<\/li>\n<\/ul>\n\n\n\n

    This means that a person can have fat in the liver<\/strong> and you find out only during a blood test, ultrasound, or other research carried out for a different reason.<\/p>\n\n\n\n

    In the absence of symptoms does not allow us to say that the liver is normal.<\/p>\n\n\n\n

    How is the diagnosis made?<\/h2>\n\n\n\n

    The diagnosis does not rely on a single study.<\/p>\n\n\n\n

    Your doctor may consider these factors:<\/p>\n\n\n\n

      \n
    • the history of the organization.<\/li>\n\n\n\n
    • the consumption of alcohol;<\/li>\n\n\n\n
    • the drugs used.<\/li>\n\n\n\n
    • weight and waist circumference;<\/li>\n\n\n\n
    • blood sugar (glucose);<\/li>\n\n\n\n
    • serum cholesterol and triglycerides;<\/li>\n\n\n\n
    • examination of liver enzymes;<\/li>\n\n\n\n
    • examination of the picture.<\/li>\n<\/ul>\n\n\n\n

      Ultrasound, elastography, magnetic resonance imaging, and other methods that can be used in specific situations.<\/p>\n\n\n\n

      In some cases, a liver biopsy is necessary to assess inflammation and fibrosis) with higher accuracy.<\/p>\n\n\n\n

      For this reason, a test showing a \u201csteatosis\u201d and does not account alone, the entire story of the fat in the liver<\/strong>.<\/p>\n\n\n\n

      Where to Tirzepatida play into this story?<\/h2>\n\n\n\n

      The Tirzepatida acts on the receptors for GIP and GLP-1.<\/p>\n\n\n\n

      Among its purposes are the following:<\/p>\n\n\n\n

        \n
      • the reduction of appetite;<\/li>\n\n\n\n
      • the increase of the time;<\/li>\n\n\n\n
      • the improved control of blood glucose levels;<\/li>\n\n\n\n
      • the improvement of insulin sensitivity;<\/li>\n\n\n\n
      • a significant reduction of body weight in most patients.<\/li>\n<\/ul>\n\n\n\n

        These side effects are among the mechanisms that are described by the Fda for the Tirzepatida.<\/p>\n\n\n\n

        These factors are not directly related to your metabolism, which influences the fat in the liver<\/strong>.<\/p>\n\n\n\n

        But the researchers also wanted to know if the effect could be measured directly on the board.<\/p>\n\n\n\n

        This is exactly what some of the studies that have begun to be investigated.<\/p>\n\n\n\n

        In the study, SURPASS-3 MRI, we evaluated the fat of the liver, either directly<\/h2>\n\n\n\n

        One of the most interesting studies was to SURPASS-3 MRI.<\/p>\n\n\n\n

        This sub-involved persons with type 2 diabetes, and the most likely to have steatosis.<\/p>\n\n\n\n

        All the participants underwent magnetic resonance imaging to measure the amount of fat in the liver.<\/p>\n\n\n\n

        After the 52 weeks to Tirzepatida was associated with a higher reduction of fat in the liver, the insulin-degludeca.<\/p>\n\n\n\n

        This result is important because it does not depend solely on the weight and \/ or blood tests. The researchers then measured directly from the fat in the liver<\/strong> by means of MRI-PDFF, which is a technique of resonance is used in research to quantify fat in the liver.<\/p>\n\n\n\n

        How to fat in the liver, it decreased in the study?<\/h2>\n\n\n\n

        On the SURPASS TO-3 MRI's, the group of Tirzepatida of the 10-mg and 15-mg combined had an average reduction in the absolute size of approximately 8 percentage points over the content of fat in the liver, as compared to about 3.4 percentage points, with the insulin-degludeca.<\/p>\n\n\n\n

        The difference between treatments was approximately 4.7 percentage points.<\/p>\n\n\n\n

        This does not mean that all people using Tirzepatida will be just such a reduction.<\/p>\n\n\n\n

        The participants had specific characteristics, and they were on the inside of a controlled clinical study.<\/p>\n\n\n\n

        Even so, the results showed a significant effect on the fat in the liver<\/strong> in that population.<\/p>\n\n\n\n

        The improvement is only true because people lose weight?<\/h2>\n\n\n\n

        Losing weight seems to play a very important role to play.<\/p>\n\n\n\n

        When there is a material reduction in the weight of the body, especially in the visceral fat, is usually occurs in the improvement of the various markers in the metabolic.<\/p>\n\n\n\n

        In a study of resonance, reduce the fat of the liver has been linked to a reduction in weight and also in the reduction of abdominal fat.<\/p>\n\n\n\n

        This makes sense biologically: to reduce the excess of adipose tissue may decrease the flow of fatty acids to the liver, and enhancing insulin sensitivity.<\/p>\n\n\n\n

        Therefore, a large part of the improvement of the fat in the liver<\/strong> most likely it is integrated into the overall effects of weight loss and improved metabolism.<\/p>\n\n\n\n

        And when there is an inflammation and fibrosis?<\/h2>\n\n\n\n

        This one is a different matter.<\/p>\n\n\n\n

        To reduce fat in the liver that is important, but the researchers also need to know if the treatment fails to improve the inflammation and scarring of the liver.<\/p>\n\n\n\n

        It was then that he entered on the study of the SYNERGY-for three years, which was evaluated Tirzepatida of people with the MASH is confirmed by biopsy, fibrosis, moderate or advanced stage F2 or F3.<\/p>\n\n\n\n

        This study is a phase 2, followed 190 participants for up to 52 weeks.<\/p>\n\n\n\n

        The main objective was to analyse the resolution of a MASH with no worsening of fibrosis.<\/p>\n\n\n\n

        The SYNERGY-I find it?<\/h2>\n\n\n\n

        The results were very significant.<\/p>\n\n\n\n

        The resolution of a MASH with no worsening of fibrosis occurred in:<\/p>\n\n\n\n

          \n
        • 44%<\/strong> of the participants, with only 5% of Tirzepatida;<\/li>\n\n\n\n
        • 56%<\/strong> 10 mg;<\/li>\n\n\n\n
        • 62%<\/strong> 15 mg;<\/li>\n\n\n\n
        • 10%<\/strong> in the placebo group.<\/li>\n<\/ul>\n\n\n\n

          The researchers also evaluated the improvement in at least one stage of fibrosis with no worsening of the MASH.<\/p>\n\n\n\n

          This result has occurred in the level.<\/p>\n\n\n\n

            \n
          • 55%<\/strong> 5 mg;<\/li>\n\n\n\n
          • 51%<\/strong> 10 mg;<\/li>\n\n\n\n
          • 51%<\/strong> 15 mg;<\/li>\n\n\n\n
          • 30%<\/strong> with placebo.<\/li>\n<\/ul>\n\n\n\n

            The data show that the effects of the Tirzepatida you can go beyond a simple reduction in the fat in the liver<\/strong> in a certain population of the research.<\/p>\n\n\n\n

            So Tirzepatida comes to the MASH?<\/h2>\n\n\n\n

            It is also important to be cautious about.<\/p>\n\n\n\n

            SYNERGY-I went on a study of the phase 2<\/strong>.<\/p>\n\n\n\n

            The authors have stated that larger studies and longer are required to evaluate the efficacy and safety of the Tirzepatida in the treatment of the MASH.<\/p>\n\n\n\n

            In addition, the positive results from a study does not mean automatically that it is a medicine that has gained a new indication for regulation.<\/p>\n\n\n\n

            In Brazil, the Tirzepatida has indicated to control blood sugar in type 2 diabetes, and for the control of chronic burden on the patients that meet the criteria that have been approved.<\/p>\n\n\n\n

            You must not assign or disclose the Tirzepatida how to fat in the liver<\/strong> it was, in isolation, an approved indication for the drug.<\/p>\n\n\n\n

            The most recent research have been added?<\/h2>\n\n\n\n

            An exploratory analysis was published subsequently, we used data from participants of the SYNERGY-for three years.<\/p>\n\n\n\n

            The researchers found that the people who presented the resolution in the MASH or in the improvement of fibrosis were also, on average, a greater body weight reduction and the improvement of the parameters of metabolism.<\/p>\n\n\n\n

            The standardization of the fat out of the liver appeared to be an important mediator of the statistician of the histological response.<\/p>\n\n\n\n

            In the simplest of terms, all of the patients who showed the best results in the liver were found to show a significant improvement in the fat in the liver<\/strong>the weight of the control of metabolism.<\/p>\n\n\n\n

            These data help to establish a clear link between metabolism and liver disease.<\/p>\n\n\n\n

            \"Pessoa
            Image illustration of a person on top of a digital scale in a clean and minimalistic style to represent follow-up of the body weight during the weight loss process.<\/figcaption><\/figure>\n\n\n\n

            To lose weight, help with no Tirzepatida?<\/h2>\n\n\n\n

            Yes.<\/p>\n\n\n\n

            Lifestyle changes and weight loss, are important components in the care of people with MASLD.<\/p>\n\n\n\n

            This means that the benefits for the liver does not depend solely on drugs.<\/p>\n\n\n\n

            A routine that encourages a:<\/p>\n\n\n\n

              \n
            • power to appropriate;<\/li>\n\n\n\n
            • physical activity;<\/li>\n\n\n\n
            • the reduction of excess weight;<\/li>\n\n\n\n
            • the control of glucose;<\/li>\n\n\n\n
            • the control of the tg;<\/li>\n\n\n\n
            • the treatment of high blood pressure;<\/li>\n\n\n\n
            • adequate sleep;<\/li>\n<\/ul>\n\n\n\n

              you can help to improve the health of metabolism.<\/p>\n\n\n\n

              In this context, the Tirzepatida needs to be understood within a wider strategy, and not as a replacement for all of those taken care of.<\/p>\n\n\n\n

              Physical activity helps the liver do?<\/h2>\n\n\n\n

              Yes.<\/p>\n\n\n\n

              Physical activity has important effects on metabolism, insulin sensitivity, and body composition.<\/p>\n\n\n\n

              Even when the change in weight is a huge exercise can improve parameters of metabolic.<\/p>\n\n\n\n

              Combine aerobic exercise with strength training is typically to bring about far-reaching benefits for your health.<\/p>\n\n\n\n

              In addition, strength training helps maintain muscle mass during weight loss.<\/p>\n\n\n\n

              This is important because the goal should be to reduce the number of balance, but improving body composition and metabolism can influence the health of the liver.<\/p>\n\n\n\n

              I need to eliminate carbs?<\/h2>\n\n\n\n

              No.<\/p>\n\n\n\n

              There is no universal need to remove the carb and take care of the health of the liver.<\/p>\n\n\n\n

              The quality and quantity of the total power is more important than it is to turn a single nutrient in the back.<\/p>\n\n\n\n

              A well-balanced diet can include foods such as:<\/p>\n\n\n\n

                \n
              • rice,<\/li>\n\n\n\n
              • bean;<\/li>\n\n\n\n
              • fruit;<\/li>\n\n\n\n
              • it is;<\/li>\n\n\n\n
              • potato<\/li>\n\n\n\n
              • loaves of bread;<\/li>\n\n\n\n
              • the masses;<\/li>\n\n\n\n
              • the other grains.<\/li>\n<\/ul>\n\n\n\n

                The one thing to watch for is the general standard for food, especially an excess of energy drinks, sweet, food, and ultraprocessados in large amounts, and a low consumption of nutrient-rich foods.<\/p>\n\n\n\n

                In the case of the fat in the liver<\/strong>a sustainable strategy is usually more useful than the constraints of stress.<\/p>\n\n\n\n

                It is the only one responsible for the steatosis?<\/h2>\n\n\n\n

                No.<\/p>\n\n\n\n

                The disease is multi-factorial.<\/p>\n\n\n\n

                An excess of energy, insulin resistance, obesity, visceral, genetic predisposition, type 2 diabetes, changes in serum lipids and other factors that are involved.<\/p>\n\n\n\n

                High consumption of sugary drinks and low-quality diets can help it, but to reduce the whole of the explanation for the \u201ceating sugar\u201d is a misnomer.<\/p>\n\n\n\n

                A person can have fat in the liver<\/strong> even without consuming large quantities of sweets.<\/p>\n\n\n\n

                For this reason, the treatment, you need to consider the frame's metabolism as a whole.<\/p>\n\n\n\n

                Alcohol is worthy of attention<\/h2>\n\n\n\n

                Yes.<\/p>\n\n\n\n

                When there is a buildup of fat in the liver, and to understand the pattern of alcohol consumption that is important to you.<\/p>\n\n\n\n

                The current position of the liver also takes into account metabolic factors, and the amount of alcohol consumed.<\/p>\n\n\n\n

                For this reason, the provider is generally a question about the consumption of alcoholic beverages during the investigation.<\/p>\n\n\n\n

                This will help you to differentiate between the possible causes and to classify the disease.<\/p>\n\n\n\n

                It is not appropriate to assume that all of fat in the liver<\/strong> it is automatically caused only by metabolism, or by the weight.<\/p>\n\n\n\n

                The enzymes in the liver of the normal discard steatosis?<\/h2>\n\n\n\n

                Don't have to be.<\/p>\n\n\n\n

                Tests such as ALT and AST, can provide you with important information, but that may be normal, even in people with liver disease, esteat\u00f3tica.<\/p>\n\n\n\n

                For this reason, the diagnosis should not rely on the value alone.<\/p>\n\n\n\n

                The historical, clinical, risk factors, imaging and, when necessary, with other methods to help you assess the situation.<\/p>\n\n\n\n

                If there is a high risk of steatosis, normal subjects are not to be construed as a guarantee of the absence of a condition as well.<\/p>\n\n\n\n

                The ultrasound shows it all about?<\/h2>\n\n\n\n

                An ultrasound is a test that is used, and it can identify steatosis in a variety of situations.<\/p>\n\n\n\n

                But it does have its limitations.<\/p>\n\n\n\n

                He is not able to accurately measure all of the levels of fat, and it's not the best way to determine a yourself in the presence of inflammation and stage of fibrosis.<\/p>\n\n\n\n

                Other tests may be necessary, depending on the individual's risk.<\/p>\n\n\n\n

                So, to find out fat in the liver<\/strong> the equipment may only be the beginning of a trial, and it's not the end of it.<\/p>\n\n\n\n

                Cf is most troubled?<\/h2>\n\n\n\n

                Fibrosis is one of the most important characteristics of the data to estimate the risk to the future health of the liver metabolism.<\/p>\n\n\n\n

                It represents the formation of a scar in the liver tissue.<\/p>\n\n\n\n

                The most advanced fibrosis, the more it tends to be a risk of progression to complications such as cirrhosis.<\/p>\n\n\n\n

                It is for this reason that the research did not assess just how much of fat in liver.<\/p>\n\n\n\n

                Some studies, such as the SYNERGY-I also look at whether the treatments are able to improve on the stage of fibrosis with no worsening of the inflammation.<\/p>\n\n\n\n

                The fat on the liver can turn into cirrhosis?<\/h2>\n\n\n\n

                It can be made in a portion of patients, especially when there are MASH and the fibrosis phase.<\/p>\n\n\n\n

                This doesn't mean that every person who is diagnosed with steatosis have cirrhosis.<\/p>\n\n\n\n

                Many people continue to have less advanced disease.<\/p>\n\n\n\n

                The risk depends on many different factors, such as:<\/p>\n\n\n\n